Stock 0QF MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Moderna, Inc. BOERSE MUENCHEN

Equities

0QF

US60770K1079

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN
Other stock markets
 03:43:15 2024-06-28 pm EDT 		5-day change 1st Jan Change
111 EUR -2.55% Intraday chart for Moderna, Inc. -11.17% +23.69%
Jun. 28 Moderna: positive CHMP opinion on RSV CF
Jun. 28 Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,518 41,340 102,976 69,006 37,919 45,510 - -
Enterprise Value (EV) 1 5,548 36,842 92,848 59,104 29,315 39,260 41,343 42,511
P/E ratio -12.6 x -53.3 x 8.98 x 8.93 x -8.07 x -17 x -22.6 x -72.2 x
Yield - - - - - - - -
Capitalization / Revenue 108 x 51.5 x 5.58 x 3.58 x 5.54 x 11 x 9.46 x 6.94 x
EV / Revenue 92.1 x 45.9 x 5.03 x 3.07 x 4.28 x 9.45 x 8.6 x 6.49 x
EV / EBITDA -10.8 x -50.3 x 6.86 x 6.05 x -8.1 x -14 x -19.6 x -60.9 x
EV / FCF -11.3 x 18.8 x 6.96 x 12.9 x -7.66 x -16.7 x -19.5 x -38.8 x
FCF Yield -8.84% 5.32% 14.4% 7.75% -13% -5.99% -5.14% -2.58%
Price to Book 6.14 x 16.3 x 7.24 x 3.7 x 2.74 x 4.07 x 5.05 x 6 x
Nbr of stocks (in thousands) 333,250 395,710 405,450 384,180 381,284 383,240 - -
Reference price 2 19.56 104.5 254.0 179.6 99.45 118.8 118.8 118.8
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 60.21 803.4 18,471 19,263 6,848 4,154 4,809 6,554
EBITDA 1 -514.7 -731.9 13,528 9,768 -3,618 -2,810 -2,113 -697.8
EBIT 1 -545.7 -763.1 13,296 9,420 -4,239 -3,052 -2,312 -928.3
Operating Margin -906.38% -94.99% 71.98% 48.9% -61.9% -73.46% -48.07% -14.16%
Earnings before Tax (EBT) 1 -514.7 -744.5 13,285 9,575 -3,942 -2,628 -1,976 -92.77
Net income 1 -514 -747.1 12,202 8,362 -4,714 -2,695 -2,054 -482.4
Net margin -853.73% -92.99% 66.06% 43.41% -68.84% -64.88% -42.71% -7.36%
EPS 2 -1.550 -1.960 28.29 20.12 -12.33 -6.987 -5.258 -1.646
Free Cash Flow 1 -490.5 1,960 13,336 4,581 -3,825 -2,353 -2,124 -1,097
FCF margin -814.7% 243.91% 72.2% 23.78% -55.86% -56.63% -44.17% -16.74%
FCF Conversion (EBITDA) - - 98.58% 46.9% - - - -
FCF Conversion (Net income) - - 109.29% 54.78% - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 7,211 6,066 4,749 3,364 5,084 1,862 344 1,831 2,811 167 140.1 1,499 2,151 574 422.7
EBITDA 1 5,488 - - - - - - - 208 - -1,351 -493.1 -186.9 - -
EBIT 1 5,410 4,227 2,447 1,166 1,580 -366 -1,867 -2,012 6 -1,266 -1,338 -510.2 61.42 -970.8 -1,085
Operating Margin 75.02% 69.68% 51.53% 34.66% 31.08% -19.66% -542.73% -109.89% 0.21% -758.08% -955.01% -34.03% 2.86% -169.13% -256.57%
Earnings before Tax (EBT) 1 5,410 4,229 2,474 1,217 1,655 -305 -1,749 -1,958 70 -1,165 -1,268 -429.4 184.8 -918.2 -994.8
Net income 1 4,868 3,657 2,197 1,043 1,465 79 -1,380 -3,630 217 -1,175 -1,295 -457.5 209 -918.2 -994.8
Net margin 67.51% 60.29% 46.26% 31% 28.82% 4.24% -401.16% -198.25% 7.72% -703.59% -924.51% -30.52% 9.72% -159.97% -235.33%
EPS 2 11.29 8.580 5.240 2.530 3.610 0.1900 -3.620 -9.530 0.5500 -3.070 -3.350 -1.109 0.5267 -2.729 -2.810
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/4/22 8/3/22 11/3/22 2/23/23 5/4/23 8/3/23 11/2/23 2/22/24 5/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 971 4,498 10,128 9,902 8,604 6,250 4,167 2,999
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -491 1,960 13,336 4,581 -3,825 -2,353 -2,124 -1,097
ROE (net income / shareholders' equity) -38% -40% 146% 50.3% -28.6% -22.5% -19% -10.5%
ROA (Net income/ Total Assets) -28.9% -16.7% 76.2% 33.1% -21.3% -16.5% -14.1% -7.21%
Assets 1 1,776 4,463 16,003 25,264 22,142 16,355 14,548 6,688
Book Value Per Share 2 3.190 6.420 35.10 48.50 36.30 29.20 23.50 19.80
Cash Flow per Share 2 - 5.320 31.60 12.00 -8.160 -6.940 -4.540 1.890
Capex 1 31.6 67.4 284 400 707 881 490 522
Capex / Sales 52.41% 8.4% 1.54% 2.08% 10.32% 21.22% 10.19% 7.96%
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8 USD
Average target price
145.9 USD
Spread / Average Target
+22.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LONZA GROUP AG Stock Lonza Group AG
+38.65% 38.13B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.64B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. 0QF Stock
  5. Financials Moderna, Inc.